Based on our expertise on antibody engineering and biological knowledge, we are developing TNFRSF agonistic monoclonal, bispecific, and multispecfic antibodies via our series of xLinkAb platforms.
Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines. Pleasecontact us to explore collaboration opportunities.
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.